Introduction
Ovarian cancer is a complex disease that remains difficult to diagnose at early stages and hence is difficult to treat (Bast et al., 2009; Cho, 2009; Cho and Shih, 2009) . Epithelial ovarian cancers are subdivided into four major categories based on histological criteria and resemblance to epithelial components of the normal female reproductive tract (Cho and Shih, 2009 ). Approximately 70% of ovarian carcinomas are categorized as serous tumors because their histoarchitecture recapitulates the epithelium lining the human fallopian tube. Other categories include endometrioid, mucinous and clear cell subtypes (Bast et al., 2009; Cho and Shih, 2009) . Ovarian carcinomas are also classified as either low-grade or high-grade tumors. Clinically, low-and high-grade ovarian cancer behaves very differently, with low-grade cancers being more resistant to cytotoxic chemotherapy (Cho and Shih, 2009) . Whereas lowgrade tumors frequently exhibit alterations (mutations, deletions or amplifications) of genes in the Kras and Pten/PI3K pathways, high-grade tumors are associated frequently with mutations (or deletions) in the tumor repressor protein (Trp53; p53) gene (Cho and Shih, 2009 ) and may be derived from fimbrial epithelial cells of the distal fallopian tube Lee et al., 2007) as well as from ovarian surface epithelial (OSE) cells (Auersperg et al., 2008) . Highgrade tumors may also exhibit amplification of PIK3CA (Astanehe et al., 2008; Roh et al., 2010) suggesting a link between PTEN and p53. Recent gene profiling and sequencing databases have identified mRNAs and microRNAs relatively overexpressed or underexpressed in various ovarian cancer subtypes (Page et al., 2006; Kobel et al., 2008; Konstantinopoulos et al., 2008; Bast et al., 2009; Creighton et al., 2010; Despierre et al., 2010) . However, our understanding this complex disease remains limited and continues to evolve as new information on the potential sites of origin and molecular pathways involved is obtained (Crum et al., 2007; Lee et al., 2007; Auersperg et al., 2008; Karst and Drapkin, 2010) .
To help understand the etiology of human ovarian cancer, several mouse models of this disease have been devised in recent years using novel, pioneering strategies. Oncogenes introduced into dispersed Trp53 null ovarian cells using in vitro and in vivo approaches and avian retroviral receptors generated epithelial cell tumors (Orsulic et al., 2002) (Wu et al., 2007) mutations, characterized as poorly differentiated carcinomas, endometrioid-like adenocarcinomas, endometrioid adenocarcinomas, respectively. Although the adenoviral injection approach has been a major breakthrough, it depends on a highly technical intervention that can deliver the vectors to bursal and/or oviductal cells in addition to the OSE, thereby obscuring the identity of the actual transformed cell type(s) (ClarkKnowles et al., 2009) . The anti-Mullerian hormone receptor (AMHR2) is expressed in multiple cells types, including Mullerian-derived OSE cells, stromal cells of the oviduct and uterus as well as ovarian granulosa cells (Jamin et al., 2002; Fan et al., 2008; Xing et al., 2009) . When the Amhr2 promoter was used to drive expression of the SV40T antigen, ovarian carcinomas developed with B50% penetrance (Connolly et al., 2003) verifying expression of Amhr2-Cre in OSE cells. More recently, when the Amhr2-Cre mice were used to disrupt the Brca1 and p53 genes (Xing et al., 2009) , uterine leiomyosarcomas developed rapidly indicating that uterine Amhr2-Cre expressing smooth muscle cells are acutely sensitive to these particular mutations. Importantly, activation of the PI3K pathway by loss of Pten (Pten fl/fl ;Amhr2Cre mice) (Lague et al., 2008; Fan et al., 2009a, b) or overexpression of PI3K (Pik3ca;Amhr2Cre mice) (Liang et al., 2009) or activation of the KRAS pathway by expression of stable mutant KRAS G12D (Kras G12D ;Amhr2Cre mice) (Fan et al., 2009a, b) alone does not lead to ovarian cancer but can enhance OSE cell proliferation and metaplasia (Liang et al., 2009) .
Recent studies from our laboratory have shown that activation of the rat sarcoma GTPase (RAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1) and extracellular signal-regulated kinase (ERK)1/2 pathway directs specific cell fate decisions of ovarian granulosa cells in growing and preovulatory follicles as well as in cells that comprise the ovarian surface epithelium (Fan et al., 2009a, b) . In preovulatory follicles activation of RAS and ERK1/2 by the luteinizing hormone (LH) surge is essential for ovulation and terminal differentiation of granulosa cells (Fan et al., 2009a, b) . Conversely, premature expression of a mutant stable KRAS (KRAS G12D ) in granulosa cells of the Kras
G12D
;Amhr2Cre mice completely derailed early follicle development . Granulosa cells ceased dividing, failed to undergo apoptosis and did not differentiate. As Kras G12D mutant granulosa cells expressed high levels of the tumor-suppressor PTEN, we further disrupted the Pten gene in the Kras G12D ; Amhr2Cre mouse strain. Surprisingly, the fate of granulosa cells in the abnormal follicles was not markedly altered in the Kras G12D ; Pten;Amhr2Cre double mutant mice. However, the OSE cells developed into low-grade serous papillary adenocarcinomas (as classified by expert mouse and human pathologists) with 100% penetrance and died within 4-6 months of age because of tumor volume (Fan et al., 2009a, b) . Therefore, the Pten fl/fl ;Kras G12D ;Amhr2-Cre mice provide the first evidence that granulosa cells are highly resistant to many oncogenic insults that profoundly impact OSE cells Fan et al., 2009a, b) , thereby explaining why granulosa cell tumors have not been observed in the previous studies (Orsulic et al., 2002; Connolly et al., 2003; Fan et al., 2009a, b) .
Importantly, the low-grade serous adenocarcinomas of the Pten fl/fl ;Kras
;Amhr2-Cre mutant mice represent the first mouse model of this specific ovarian cancer subtype (Fan et al., 2009a, b) . The spontaneous and reproducible development of serous adenocarcinomas in these mice have lead us to determine what molecular pathways are altered in these cells and if this model can be used to understand the molecular events controlling the transformation of OSE cells and thereby provide some insights into this cancer subtype in women.
In particular, this model, unlike other models, affords the opportunity to track the initiation of transformation of OSE cells at early stages in vivo by determining when the mutant OSE cells first exhibit altered morphology and functions and what signaling pathways are required to maintain transformation in the OSE cells in this context. The striking increases Mullerian cell markers in the OSE tumors indicate that these cells can differentiation into a fallopian-like epithelium. In addition, the consistent increases in Trp53 expression and its target microRNA, miR-34a-c indicate that altered activation of the phosphatidylinositol 3 kinase (PI3K) and RAS pathways is tightly linked to regulation of TRP53 levels and presumably function in these cells. ;Amhr2-cre mice as early as 5 weeks of age and express markers of human serous adenocarcinomas Histological sections prepared from ovaries of control mice at 5 and 10 weeks of age show that the OSE cell layer is comprised on a single layer of meso-epithelial cells as reported by others (Auersperg et al., 2001; Orsulic et al., 2002) . These cells stain for the epithelial cell markers cytokeratin 8 (Fan et al., 2009a, b) and for E-cadherin (CDH1) but not for vimentin ( Figure 1a) . In contrast, the OSE layer present in ovaries of the Pten fl/fl ;Kras
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;Amhr2-Cre mice exhibits visible changes in morphology with obvious epithelial cell hyperplasia evident as early as 3 weeks of age in some ovaries and at 5 weeks in all ovaries. By 10 weeks of age, all mice exhibited low-grade serous, papillary-like adenocarcinomas as classified by expert pathologists (Figure 1a ).
Of note, the OSE tumor cells stain for cytokeratin 8 (Fan et al., 2009a, b) and vimentin but not for E-cadherin (Figure 1a) suggesting that the cells have undergone an epithelial to mesenchymal type of transformation (Lee et al., 2006) . Furthermore, the OSE tumor cells do not stain for calretinin, a marker of Figure 1 Temporal changes in OSE cell morphology and expression of specific genes associated with the serous adenocarcinoma phenotype in the Pten;Kras G12D ;Amhr2-cre mice. (a) Hematoxylin and eosin (H&E) and immuno-labeling of ovarian sections from WT and mutant mice at 5 and 10 weeks of age. (b) Gene expression patterns in whole ovaries of WT or tumor-bearing (T) Pten;Kras G12D ;Amhr2-cre mice at 5 and 10 weeks of age.
mesotheliomas and do not exhibit atypic nuclear morphology observed in high-grade adenocarcinomas (Supplementary Figure 1) . However, the tumor OSE cells do stain positive for estrogen receptor alpha (ESR1), providing additional evidence that these tumors represent low-grade adenocarcinomas (Supplementary Figure 1) (Wong et al., 2007) .
To identify specific genes expressed in the tumorbearing ovaries at 3 months of age, total RNA was extracted from ovaries of control (wild-type (WT)) and Pten Table S1 ). These include potential regulators of stem cells (Angtpl7) (Zhang et al., 2006) , markers of cancer cells (Nov, also known as Ccn3 (Bohlig et al., 2008) , Mela and Ptgs2) (Wang and DuBois, 2010) , specific cytokines (Gkn1, Gnk2 ) and the acute phase factor (Hp) (Abdullah et al., 2009 ).
When we compared our microarray data derived from normal ovaries and tumor-bearing ovaries of Pten (GlaxoSmithKline GSK, 2008) .
The data sets from our tumor-bearing ovaries also exhibit overlapping expression with data sets from human ovarian cancers (as compared with normal ovary): 330 genes in human serous tumors and 331 in the mucinous tumors (Figures 2a and c) (Malpica et al., 2004) . Among the common genes are Cp, Lcn2, Dmkn, Msln, Cldn3, Podxl, Esr1 and Muc16 as well as specific Mullerian epithelial marker genes, Wt1, Pax8, Hoxa9 and Hoxa10. Genes encoding matrix components were also observed (Schwartz et al., 2002; Malpica et al., 2004; Santin et al., 2004; Cheng et al., 2005; Kobel et al., 2008; Konstantinopoulos et al., 2008; Cho and Shih, 2009; Gorringe and Campbell, 2009; Despierre et al., 2010; Gava et al., 2008) (Supplementary Table S3 ). That many of the genes in the mouse and human ovarian cancer samples are common to the cancer cell Kras signature indicates that activation of Kras pathway (by mutations or other mechanisms) may be an underlying common feature of transformed OSE and Mullerian cells. As a high percentage human ovarian cancer samples are likely to be high-grade serous adenocarcinomas, these tumors may harbor defects not only in the function of TP53 but also changes in the MET-RAS signaling pathway (Corney et al., 2010; Zhao et al., 2010) .
Real-time reverse transcriptase-PCR results using RNA prepared from control and the tumor-bearing ovaries confirmed the Microarray data, documented age-dependent changes in gene expression profiles and verified upregulation of specific genes known to be expressed in human ovarian cancers ( Figure 1b) . Cp, Podxl and Ptgs2 were expressed at elevated levels by 5 weeks of age whereas Cldn3, Dmkn, Krt8, Lcn2, Msln and Angptl were elevated at 10 weeks. Wt1, Pax8, Hoxa9 and Hoxa10 were also elevated in the mouse tumor tissue at 10 weeks of age indicating that these cells had acquired specific characteristics of Mullerian (fallopian tube/endometrial) epithelial cells. Expression of the Trp53 (p53) was also elevated in the tumor cells providing further evidence that there are distinct temporal changes in gene expression patterns in the mutant OSE cells.
Most genes expressed at reduced levels in the tumorbearing ovaries from the Pten fl/fl ; Kras G12D ;Amhr2-cre mice compared with controls are oocyte (*) or granulosa cell specific (Supplementary Table S4 ) and reflect the loss of oocytes and altered granulosa cell differentiation in the abnormal follicle structures (Supplementary Table  S2 ) present in these ovaries .
Tumor-related genes are selectively expressed in OSE cells To determine which of the genes associated with the tumor-bearing ovary at 5 and 10 weeks of age were expressed specifically in purified OSE cells, we isolated OSE cells from ovaries of WT and Pten fl/fl ; ;Amhr2-Cre mice. The WT and mutant OSE cells (cytokerain 8 positive) were removed from the epithelium by mild-trypsin digestion (Figure 3a , upper panel). The highly purified OSE cells from WT ovaries appear morphologically homogeneous in culture as indicated by the characteristic cuboidal-cell shape (Figure 3a , middle panel) and uniform immunolabeling of cytokeratin 8 and E-cadherin (Figure 3a , lower panel) as would be predicted from their presence in vivo (Figures 1 and 3a) .
Several genes (Cldn3, Dmkn, Msln and Lcn2) were higher in the purified WT OSE cells compared with WT whole ovaries (Figure 3b) , suggesting that these genes are specific markers of OSE cells and function in the non-transformed epithelium. Furthermore, the expression of Wt1, Pax8, Hoxa9 and Hox10, specific markers of Mullerian-derived (fallopian and endometrial) epithelia (Cheng et al., 2005; Ko et al., 2010) were induced in the mutant mouse OSE cells (Figure 3b) . These results document unequivocally that mouse OSE cells can acquire Mullerian duct markers during transformation by disrupting Pten and expressing mutant Kras G12D . Differential gene expression patterns in the mutant OSE cells were observed: some genes were elevated selectively in cells from 10 weeks (Hoxa9, Dmkn, Lcn2 and Podxl) whereas others were elevated at 5 and 10 weeks (Cp, Cldn3, Krt8, Msln, Ptgs2, Wt1 and Angptl7). A striking increase in Trp53 mRNA and protein were also observed in the mutant OSE cells compared with WT cells (Figure 3c ). ;Amhr2-Cre OSE cells were injected into recipient mice in vivo, ectopic tumors positive for cytokeratin 8 developed rapidly Figure 2 Genes overlapping between the Pten;Kras;Amhr2-cre gene signature and relevant signatures from human cancers. (a) Overlaps between the set of human orthologs high (fold#2) in Pten;Kras;Amhr2-cre mice (compared with WT mice) and various sets of genes derived from human data sets: genes high/low (Po0.01, t-test) in k-ras mutant versus k-ras WT cell lines, and genes high/low (Po0.05) in serous, mucinous, or endometrioid ovarian cancers, as compared with normal ovary. Numbers of genes in each set indicated in parentheses. Numbers overlapping between sets were compared with chance expected. *Po1E-20, one-sided Fisher's exact; **Po1E-6, one-sided Fisher's exact. (within 2 weeks) in the peritoneal cavity, at subcutaneous sites and under the kidney capsule where invasive activity into the kidney capsule was evident (Figure 4d) . Thus, these transformed cells are highly proliferative and possess invasive activity.
OSE cells isolated from ovaries of the
The PI3K/AKT signaling pathway and ERK1/2 impact in the functions of the mutant OSE cells The disruption of Pten and expression of mutant KRAS G12D are expected to increase the activity of the PI3K/AKT and RAS/MEK1/ERK1/2 pathways, respectively. However, there is also important cross-talk between these pathways and increasing evidence indicates that activation of the PI3K pathway is essential to maintain the growth promoting and transformation effects of KRAS (Miller et al., 2009) , in part, by blocking negative feedback regulatory loops (Wee et al., 2009) . Therefore, we determined if pharmacological disruption of either PI3K or MEK1/ ERK1/2 activity would prevent colony formation and/ or the expression of selected genes. As shown in Figure 5a , AKT and ERK1/2 are phosphorylated and hence activated in OSE cells isolated from ovaries of tumor-bearing mice at 10 weeks of age and this was blocked by blocked by inhibitors of PI3K (LY294002) and MEK1 (U0126), respectively. PTEN was undetectable and Foxo1 mRNA was markedly reduced in the mutant OSE cell (data not shown). When U0126 and/or LY294002 were added to the soft agar, they inhibited colony formation by approximately 70-90% (Figure 5b ). Loss of colony formation was associated with reduced expression of specific genes including Cp, Ptgs2, Dmnk, Lcn2 and Ptgs2 that were selectively down-regulated by inhibition of PI3K as well as Ccnd1,Cldn3, Krt8, Podxl and W1t that were reduced by either the PI3K/AKT or ERK1/2 signaling cascade inhibitors. Angptl7 was increased selectively by the PI3K inhibitor whereas Trp53 mRNA and protein were reduced equally by either LY294002 or UO126 (Figures 5c and d) . Thus, the PI3K/AKT and MEK/ERK1/2 pathways are required to drive and maintain transformation of the mutant OSE cells. ;Amhr2-Cre mice. These include Podxl, markers of Mullerian epithelium (Wt1 and Hoxa9), Trp53 and one of its target genes Cdkn1a (p21) as well as a marker of serous adenocarcinomas, Cldn3. These genes were less dramatically increased in the Kras G12D ; Amhr2-Cre mice indicating that disrupting the PI3K pathway alone exerts the more potent response in this context (Figure 6b ). 
Specific microRNAs are regulated in the mutant OSE cells compared with WT OSE cells
MicroRNAs comprise an extensive class of non-coding nucleic acids that govern broad gene regulatory pathways in development (Stafani and Slack, 2008 Creighton et al., 2010) . Those highlighted most frequently are members of the Let-7 cluster that regulate (K/H)RAS and Hmga2, a potent regulator of proliferation (Roush and Slack, 2008) , miR-21 that is transcriptionally controlled by STAT3, AP1 factors and/or TRP53 (Krichevsky and Gabriety, 2009 ) and regulates such diverse processes as cell proliferation, invasion and migration (Krichevsky and Gabriety, 2009 ), miR-34a/c that are targets of TRP53 and potent inhibitors of the cell growth regulators (Hermeking, 2007; Ji et al., 2009) , miR-29a that is a target of WNT/CTNNB1 (Kaplinas et al., 2009 ) and regulates Trp53 (Park et al., 2009) , miR-125b that may target RAS (Rybak et al., 2008) and miR-214 that impacts the level of mRNA encoding the tumorsuppressor Pten (Yang et al., 2008) .
On the basis of these studies, we analyzed several microRNAs in our WT and mutant OSE cells in culture (Figure 7a ). We show that primary transcripts of Let-7f and miR-21, miR-29a, miR-34a, miR-34c, miR-125b-5p, miR-199a-5p, miR-720 and miR-1937 were increased dramatically in the mutant cells isolated from tumors of mice at 5 and 10 weeks of age compared with WT cells whereas miR-31 was dramatically reduced. These results indicate that transcription of these microRNAs is being regulated in the mutant mouse OSE cells. The expression of the mature forms of these microRNAs was verified for Let-7f and miR-34a (Figure 7b ). With the exception of miR-31, the expression of these microRNAs is regulated by inhibitors of PI3K (LY294002) or MEK1/ERK1/2 (U0126). Of particular interest is the down-regulation of miR-21, miR-29a, miR-34c, miR125b-5p and miR-720 in response to U0126 indicating that ERK1/2 is a potent regulator of these microRNAs. Other microRNAs (miR-29a, miR-199a-5p and miR-1937) were potently downregulated by both inhibitors. Additionally, miR-34a, like Trp53, was increased in cells lacking Pten alone, whereas miR-31 was selectively suppressed in cells expressing Kras ;Amhr2-Cre mice are the first to recapitulate diagnostic aspects of the human lowgrade serous subtype (Schwartz et al., 2002; Malpica et al., 2004) is supported by several observations. Comparisons of microarray databases show highly significant overlap in genes expressed in the mouse and human tumor cells. Importantly, the Kras/Pten mutant cells but not WT OSE cells express Wt1, Hoxa9, Hox10 and Pax8 genes that are characteristic markers of fallopian/Mullerian epithelia (Kurman and Shih, 2010) . The expression of Hoxa9 is of particular interest because it is not only important for normal tissue development but is highly expressed in other cancer cell types, including leukemias and astrocytomas (Costa et al., 2010) where it is thought to maintain the survival of progenitor cells and to be regulated by PI3K (Costa et al., 2010) . Other genes that are upregulated in the mutant mouse OSE cells are similar to ones that are enhanced in human ovarian serous adenocarcinomas (Schwartz et al., 2002; Malpica et al., 2004; Santin et al., 2004; Kobel et al., 2008; Konstantinopoulos et al., 2008; Cho and Shih, 2009; Gorringe and Campbell, 2009; Despierre et al., 2010; Gava et al., 2008) . These include Cldn3 and Msln that are increased preferentially in serous adenocarcinomas expressing Hoxa9 (Cheng et al., 2005) . Thus, although recent evidence suggests that some ovarian cancers, especially high-grade serous adenocarcinomas, may be derived from mutant fallopian tube or endometrial epithelial cells that migrate to the ovarian surface (Crum et al., 2007; Lee et al., 2007; Dubeau, 2008; Karst and Drapkin, 2010; Kurman and Shih, 2010; Roh et al., 2010) , our results and those of others (Orsulic et al., 2002; Connolly et al., 2003; Flesken-Nikitin et al., 2003; Dinulescu et al., 2005; Wu et al., 2007) document that mouse OSE cells can transform if exposed to specific oncogenic insults and that they may have some characteristics of multi-potent cells (Auersperg et al., 2008; Bowen et al., 2009) .
Many microRNAs expressed in the mutant mouse OSE tumor cells are also present in human ovarian cancer. Of particular relevance are members of the Let-7 cluster (Roush and Slack, 2008 ) that regulate Kras, miR-21 (Krichevsky and Gabriety, 2009 ) that is regulated by Kras, miR-34a/c that are transcriptional targets of TRP53 and potent inhibitors of the cell growth and therefore appear to act as tumor suppressors (Hermeking, 2007; Ji et al., 2009) , miR-29a (Kaplinas et al., 2009 ) that regulates Trp53 (Park et al., 2009) , miR-125b that may target RAS (Rybak et al., 2008) and miR-214 that impacts the level of mRNA encoding the tumorsuppressor Pten (Yang et al., 2008) . That these miRNAs have been detected in various human ovarian cancer samples underscores their potential regulatory roles in the initiation and/or maintenance of the transformed phenotype. That many miRNAs were highest in mutant OSE cells isolated from ovaries of mice at 5 weeks indicates that the molecular activities as well as the growth rate of the mutant OSE cells change with time and tumor growth.
The molecular basis of the different histological phenotypes of ovarian cancer subtypes remains puzzling. For example, the serous adenocarcinomas of the Pten fl/fl ;Kras
G12D
;Amhr2-Cre mice described herein (Fan et al., 2009a, b) differ in their histological architecture from the endometrioid-like OSE tumors in the mice reported by (Dinulescu et al., 2005) . Although the same mutant Pten and Kras G12D mouse strains were used, the tumors in each model were generated by different approaches and in OSE cells at different stages of differentiation. In our model, OSE cells are transformed by endogenous Amhr-2Cre expressed directly in these cells in vivo and in mice before puberty; hence before increases in ovarian steroid production. Conversely, the Kras and Pten mutations in the Dinulescu model were generated by adenoviral Cre injections into the ovarian bursa of mice primed with gonadotropin (Dinulescu et al., 2005) and therefore have been exposed to steroids.
As phenotypic outcome in each model appears to be highly reproducible, one plausible explanation for the distinct histological features is that the stage of OSE cell differentiation when they are exposed to the oncogenes determines the response.
Impressively, many genes selectively expressed in the Pten fl/fl ; Kras G12D ;Amhr2-Cre mouse tumor cells as well as in serous and mucinous human tumors share a common 'Kras signature' observed in other cancer cell types (Figure 2) , suggesting that activation of Kras pathway, by mutation or other mechanisms provide a mechanism that yields a common transformed outcome. Although a 'Pten signature' was not significant, selective activation of the PI3K pathway by loss of Pten in OSE cell of the Pten fl/fl ;Amhr2-Cre mice leads to specific and marked changes in mRNA and miRNA profiles in the OSE cells. Of note, Trp53, Cdkna1, Cldn3 and miR34a are increased suggesting that components of the Trp53 pathway are key targets of the PI3K pathway. Conversely, Trp53, miR-34a and miR-31 are expressed but at lower levels in the tumor cells of Pten fl/fl ; Kras G12D ;Amhr2-Cre mice and OSE cells of Kras G12D ; Amhr2-Cre mice indicating that activation of the KRAS pathway alters the effects of the PI3K pathway.
Moreover, when inhibitors of the PI3K and RAS pathways were added in culture to OSE cells already transformed, they blocked mutant OSE cell growth in soft agar and selectively altered the expression of key marker genes, indicating that both pathways are critical to maintain the transformed phenotype. As the inhibition of PI3K was more effective than inhibition of MEK1/ERK1/2 on cell growth indicates that the PI3K pathway may be a more potent driver of proliferation, perhaps involving the regulatory effects of Hoxa9 and Meis1 (Costa et al., 2010) . However, the observed potency of PI3K may also be related to the ability of PI3K to activate the RAS/MEK1/ERK1/2 pathway, thereby, stimulating both signaling cascades. Conversely, the lesser effects of U0126 indicate that blocking MEK1 and ERK1/2 disrupts only one arm of the RAS signaling cascade but will not block the effects of KRAS on PI3K or other pathways in these cells (Wee et al., 2009) . Thus, the critical role of KRAS is underscored most impressively by the extensive number of human mutant Kras target genes (B213) that are also expressed in the murine and human OSE tumors cells (Figure 2) . Collectively, these results provide strong evidence that the Pten fl/fl ; Kras
; Amhr2-Cre mouse model is relevant to a subset of the human ovarian cancers and for determining the molecular events by which these two oncogenic pathways intersect to initiate transformation and also control the TRP53 pathway.
More aggressive ovarian cancer is associated with frequent mutations or deletions of TRP53 (Cho and Shih, 2009) ;Amhr2-Cre cells to prevent more aggressive proliferation and metastatic activity (Astanehe et al., 2008 ). TRP53 appears to be active in the mutant cells because known targets are elevated selectively in the mutant OSE cells, including microRNAs, miR34a and miR34c, which have also been shown to exhibit tumor-suppressor activity, genes encoding regulators of cell proliferation such as p21 CIP (Corney et al., 2007 (Corney et al., , 2010 Hermeking, 2007) and CCN3 that regulates cell adhesion (Bohlig et al., 2008) . Thus, TRP53 and miR-34a in mouse and human low-grade adenocarcinomas may serve as an underlying negative molecular regulatory network that controls the lowgrade tumorgenicity and perhaps cytotoxic resistance of these cells.
In summary, murine OSE cells respond to known oncogenic insults, Pten deletion and Kras activation (Kras G12D ), and undergo transformation, leading to the formation of low-grade serous adenocarcinomas spontaneously in vivo. The mutant mouse OSE cells acquire morphological and biochemical characteristics of Mullerian-derived epithelial cells. Moreover, these 'differentiated' transformed cells express specific mRNA and miRNAs known to be expressed in human ovarian cancers indicating that this mouse model has relevance for understanding the specific effects of these two oncogenic factors in this cellular context and their interactions alone and together on the TRP53 pathway. ;Amhr2-Cre, mice were derived and genotyped as previously described Fan et al., 2009a, b) . 
Materials and methods
Animal procedures LSL-Kras
Histology and immunohistochemistry
Ovaries were collected and fixed in 4% parformaldehyde, embedded in paraffin and processed by routine procedures for immunohistochemisrty (Fan et al., 2009a, b) of cytokeratin 8 (ab59 400 Abcam, Cambridge, MA, USA).
Immunofluorescence
Ovaries were fixed in 4% parformaldehyde, embedded in optimal cutting temperature compound (Sakura Finetek Inc., Torrence, CA, USA) and stored at À70 1C. In all, 7 mM sections were immunostained (Fan et al., 2009a, b) with antibodies against: cytokeratin 8 (as above), E-cadherin (24E10), Vimentin (R28) from Cell Signaling (Danvers, MA, USA) and TRP53 (p53) (Sc-6243) from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Western blots
Whole cell extracts were prepared by lysing ovaries in radioimmunoprecipitation assay buffer containing protease inhibitors (Roche, Nutley, NJ, USA). Western blot analyses were performed using 30 mg of lysate protein for each sample. Cell extracts were prepared from cultured OSE cells by lysis 1 Â sodium dodecyl sulfate sample buffer at 100F for 5 min and 35 ml of each sample analyzed by western blot using antibodies, AKT and phospho-AKT (9272, 4058L), and ERK and phospho-ERK (9102, 9101S) from Cell Signaling and TRP53 (p53) (Sc-6243) from Santa Cruz Biotechnology.
Isolation and culture of primary OSE cells Ovaries were harvested from mice of indicated ages and gently washed once with serum-free Dulbecco's modified Eagle's medium-F12 media. The OSE cells were released by mild-trypsin digestion (Flesken-Nikitin et al., 2003) with modifications. The ovaries from one to five mice were then placed in a 15 ml conical tube containing 5 ml of room temperature (20-24 1C) buffer (0.25% w/v trypsin-EDTA) (Gibco/Invitrogen, Carlsbad, CA, USA) for 30 min in a 37 1C incubator with 5% CO 2 . After 30 min, the tube was gently tipped back and forth 10 times and the supernatant containing the OSE cells was transferred to a new tube and the cells collected by centrifugation at 1000 Â g for 10 min. The cells from each tube were resuspended in Dulbecco's modified Eagle's medium-F12 growth media (10% fetal bovine serum, 5% insulin-transferrin-selenium-A (Gibco/Invitrogen)) and 5% penicillin-streptomycin (Gibco/Invitrogen)) and plated in separate wells of a 24-well tissue culture plate. Fresh media was added every 2-3 days and the cells harvested when 90-100% confluent (7-10 days).
Inoculation of cells into mice
In all, 100 000 cultured OSE cells isolated from a 10-week Pten fl/fl ;Kras G12D ;Amhr2-Cre mouse were grafted along with collagen under the renal capsule of WT mice with the same genetic background. 100 000 cells were also injected subcutaneously along with Matrigel (BD Biosciences, Sparks, MD, USA) according to the manufacturer's protocol. In addition, mice were injected intraperitoneally with 100 000 cells. Tumors were harvested and fixed in 4% paraformaldehyde after 20 days.
Real-time reverse transcriptase-PCR for mRNAs, primary(pri)-miRNAs and mature miRNAs Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA) and treated with DNase I (DNA-free, Ambion Inc., Austin, TX, USA) according to the manufacturer's instructions. Complementary DNA was synthesized with a Taqman reverse transcriptase reagent kit (Applied Biosystems, Foster City, CA, USA) primed with random hexamers. Real-time PCR was performed using the Light Cycler DNA Master SYBR Green I kit (Roche Applied Sciences, Nutley, NJ, USA). Primers (Supplementary Table  S5 ) were used at a concentration of 0.5 mM and MgCl 2 at 2.4 mM. Samples were denatured for 10 min at 95 1C and then 40 cycles of 95 1C for 20 s, 60 1C for 20 s and 72 1C for 20 s as previously (Fan et al., 2009a, b) . Data were normalized to L19 using the comparative C t method. Data are presented as the mean±s.e.m of a representative of at least three experiments performed in triplicate.
Small RNAs required for detecting and measuring mature miRNAs were extracted using the mirVANA miRNA Isolation Kit (Ambion Inc.,) according to the manufacturer's instructions. Reverse transcription was performed as described above. For quantification of mature miRNAs, the TaqMan MicroRNA assay kit (Applied Biosystems) was used according to the manufacturer's instructions.
Microarray
Total RNA was prepared using the RNeasy Mini Kit (Qiagen from ovaries of control and Pten fl/fl ;Kras G12D ;Amhr2-cre mice at 3 months of age when ovaries of the mutant mice contained a substantial amount of tumor. The quality of the RNA was verified in the MicroArray Core Facility at Baylor College of Medicine and hybridized in duplicate to Mouse 420.3 Affymetrix Chips using routine procedures (Affymetrix, Santa Clara, CA, USA). ;Amhr2-cre mice were estimated, using the ratio of expression values. Expression profiles of human cell lines were obtained from Glaxo (GlaxoSmithKline GSK, 2008) and expression profiles of human ovarian tumors and normal ovary were obtained from GEO (GSE6008). Two-sided t-tests using log-transformed data determined significant differences in mean gene mRNA levels between sample groups. The mapping of transcripts or genes between the mouse signature and the human tumor array data sets was made on the Entrez Gene identifier (using the human orthologs from the mouse data set); where multiple human array probe sets referenced the same gene, the probe set with the highest variation was used to represent the gene. One-sided Fisher's exact tests determined the significance of overlap between the mouse and human gene sets (using the 15 092 unique human gene orthologs represented on the mouse array as the population). Expression patterns were visualized as color maps using the JavaTree Software (Saldanha, 2004) .
Gene expression analysis
